Inveready and the CDTI through the INNVIERTE program will invest €2.3 million of capital. This amount will be complemented by €2.7 million through other instruments and public funds that have already been obtained. With these funds, aptaTargets plans to advance up to a clinical proof of concept in acute ischemic stroke patients.